Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia

Thrombosis and Haemostasis

Volumn 79, Issue 1, 1998, Pages 50-53

  Lee, David H ^b   Warkentin, Theodore E ^a   Denomme, Gregory A ^b   Lagrotteria, Danny D ^b   Kelton, John G ^b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; HEPARIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; FEMALE; GANGRENE; GENE MUTATION; HEART INFARCTION; HUMAN; HUMAN CELL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SKIN MANIFESTATION; STROKE; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 0031974362     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614218     Document Type: Article

References (35)

1. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. Bounameaux H, ed. Marcel Dekker, New York, 1994; pp 75-127.
2. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Progr Hemost Thromb 1991; 10: 1-34.
3. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low molecular-weight heparin or unfractionated heparin. N Eng J Med 1995; 332: 1330-5.
4. Warkentin TE, Kelton JG. A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
5. Boshkov LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8.
6. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
7. 506 of factor V. Lancet 1994; 343: 1535-6.
8. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
9. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
10. 506-factor V. Blood 1995; 85: 3405-11.
11. Koster T, Rosendaal FR, de Ronde H, Briët E, Vanderbrouke JP, Bertina R. Venous thrombosis due to anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
12. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
13. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Eng J Med 1994; 330: 517-22.
14. Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. Can Med Assoc J 1996; 155: 285-9.
15. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
16. Beauchamp NJ, Martina ED, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-2.
17. Vandenbroucke JP, Koster T, Brïet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
18. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbrouke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
19. Ryan DH, Nuccie BL, Maize B, Arvan DA, Francis CW. Amplification and genotyping of coagulation factor V genomic sequence from stored frozen plasma (manuscript submitted).
20. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-7.
21. Warketin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
22. Warkentin TE, Soutar RL, Panju A, Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia (abstract). Blood 1992; 80 (suppl 1): 160a.
23. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology. Williams and Wilkins, Baltimore, MD, 1988.
24. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and possible solution. J Vasc Surg 1986; 4: 522-8.
25. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94-100.
26. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: part 2. Thromb Haemost 1996; 76: 824-34.
27. Warkentin TE. Hemostasis and atherosclerosis. Can J Cardiol 1995; 11 (Suppl C): 29C-34C.
28. Desmarais S, de Moerloose P, Reber G, Minazio A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.
29. Manten B, Westendorp RGJ, Koster T, Reitsma PH, Rosendaal FR. Risk for profiles in patients with different clinical manifestations of venous thromboembolism: A focus on the factor V Leiden mutation. Thromb Haemost 1996; 76: 510-3.
30. 506 in patients with isolated pulmonary embolism (abstract). Blood 1996; 88 (suppl 1): 172a.
31. Vandenbroucke JP, Koster T, Brïet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
32. Hellgren M, Svensson PJ, Dählback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
33. Koeleman BPC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
34. Ryan DH, Crowther MA, Ginsberg JS, Francis C. Relationship of factor V Leiden genotype to risk of acute deep vein thrombosis following joint replacement therapy. Ann Intern Med 1997; in press.
35. Donaldson MC, Belkin M, Whittemore AD, Mannick JA, Longtine JA, Dorfman DM. Impact of activated protein C resistance on general vascular surgical patients. J Vasc Surg 1997; 25: 1054-60.